{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:57:38Z","timestamp":1771977458263,"version":"3.50.1"},"reference-count":69,"publisher":"Weston Medical Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Objective: In the context of increased use of buprenorphine for pain management, comparison of real-world data (RWD) on prescription opioid nonmedical use (NMU) based on their controlled substance schedule may assist providers in providing effective pain management therapy while mitigating the risk of opioid NMU.\r\nDesign: A systematic literature review of articles reporting RWD on prescription opioid NMU involving Schedule II (CII), Schedule III (CIII), and Schedule IV (CIV) opioid medications was conducted using PubMed\u00ae.\r\nPatients\/participants: Human RWD collected in the United States from January 2010 to December 2023.\r\nMain outcome measure(s): Articles reporting RWD of prescription opioid NMU. Exclusions included buprenorphine\/methadone medications for opioid use disorder, chronic use, or overdose without clearly established NMU (could not rule out legitimate medical use).\r\nResults: There were 2,585 articles screened for inclusion, 102 articles were assessed with a validated data extraction form, and 16 articles were reviewed that compared NMU and\/or secondary NMU-related outcomes. Of these, only five articles contained RWD on NMU; all showed more NMU associated with CII than CIII or CIV opioids. Two articles evaluated buprenorphine (CIII) for analgesia and found lower rates of CIII NMU than comparator CII opioids.\r\nConclusions: Results of this systematic review support the differentiation in scheduling between CII and CIII\/CIV opioid medications with RWD. This study also reveals a research gap in comparing CIII opioid medications for analgesia to CII and CIV opioids, an area of current and future interest, considering the growing use of buprenorphine for pain management, along with initiatives to curb opioid NMU.\r\n\u00a0<\/jats:p>","DOI":"10.5055\/jom.0967","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:02:08Z","timestamp":1771974128000},"page":"77-89","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review of real-world data associated with opioid scheduling and nonmedical use"],"prefix":"10.5055","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1794-7116","authenticated-orcid":false,"given":"Suzanne K.","family":"Vosburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-4267","authenticated-orcid":false,"given":"Taryn","family":"Dailey-Govoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-6400","authenticated-orcid":false,"given":"Jody L.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3008","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"99824","doi-asserted-by":"crossref","unstructured":"Rudolf GD: Buprenorphine in the treatment of chronic pain. Phys Med Rehabil Clin N Am. 2020; 31(2): 195-204. DOI: 10.1016\/j.pmr.2020.02.001.","DOI":"10.1016\/j.pmr.2020.02.001"},{"key":"99825","doi-asserted-by":"crossref","unstructured":"Bettinger J, Batista Quevedo H, Cleary J: Emerging pharmacologic mechanisms of buprenorphine to explain experience of analgesia versus adverse effects. J Opioid Manag. 2021; 17(7): 21-31. DOI: 10.5055\/jom.2021.0639.","DOI":"10.5055\/jom.2021.0639"},{"key":"99826","doi-asserted-by":"crossref","unstructured":"Gudin J, Fudin J: A narrative pharmacological review of buprenorphine: A unique opioid for the treatment of chronic pain. Pain Ther. 2020; 9(1): 41-54. DOI: 10.1007\/s40122-019-00143-6.","DOI":"10.1007\/s40122-019-00143-6"},{"key":"99827","doi-asserted-by":"crossref","unstructured":"Tzschentke TM: Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology. 2002; 161(1): 1-16. DOI: 10.1007\/s00213-002-1003-8.","DOI":"10.1007\/s00213-002-1003-8"},{"key":"99828","doi-asserted-by":"crossref","unstructured":"Adler J, Mallick-Searle T, Garofoli M, et al.: Frontline perspectives on buprenorphine for the management of chronic pain. J Multidiscipl Healthc. 2024; 17: 1375-1383. DOI: 10.2147\/JMDH.S449748.","DOI":"10.2147\/JMDH.S449748"},{"key":"99829","doi-asserted-by":"crossref","unstructured":"Poliwoda S, Noor N, Jenkins JS, et al.: Buprenorphine and its formulations: A comprehensive review. Health Psychol Res. 2022; 10(3): 37517. DOI: 10.52965\/001c.37517.","DOI":"10.52965\/001c.37517"},{"key":"99830","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71. DOI: 10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"99831","doi-asserted-by":"crossref","unstructured":"Fishman MA, Kim PS: Buprenorphine for chronic pain: A systemic review. Curr Pain Headache Rep. 2018; 22(12): 83. DOI: 10.1007\/s11916-018-0732-2.","DOI":"10.1007\/s11916-018-0732-2"},{"key":"99832","doi-asserted-by":"crossref","unstructured":"Aiyer R, Gulati A, Gungor S, et al.: Treatment of chronic pain with various buprenorphine formulations: A systematic review of clinical studies. Anesth Analg. 2018; 127(2): 529-538. DOI: 10.1213\/ANE.0000000000002718.","DOI":"10.1213\/ANE.0000000000002718"},{"key":"99833","doi-asserted-by":"crossref","unstructured":"Dowell D, Ragan KR, Jones CM, et al.: CDC clinical practice guideline for prescribing opioids for pain\u2014United States, 2022. MMWR Recomm Rep. 2022; 71(3): 1-95. DOI: 10.15585\/mmwr.rr7103a1.","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"99834","doi-asserted-by":"crossref","unstructured":"Dowell D, Ragan KR, Jones CM, et al.: Prescribing opioids for pain\u2014The new CDC clinical practice guideline. N Engl J Med. 2022; 387(22): 2011-2013. DOI: 10.1056\/NEJMp2211040.","DOI":"10.1056\/NEJMp2211040"},{"key":"99835","doi-asserted-by":"crossref","unstructured":"Dalal S, Chitneni A, Berger AA, et al.: Buprenorphine for chronic pain: A safer alternative to traditional opioids. Health Psychol Res. 2021; 9(1): 27241. DOI: 10.52965\/001c.27241.","DOI":"10.52965\/001c.27241"},{"key":"99836","doi-asserted-by":"crossref","unstructured":"Sandbrink F, Murphy JL, Johansson M, et al.: The use of opioids in the management of chronic pain: Synopsis of the 2022 updated US Department of veterans affairs and US Department of Defense Clinical Practice Guideline. Ann Intern Med. 2023; 176(3): 388-397. DOI: 10.7326\/M22-2917.","DOI":"10.7326\/P22-0030"},{"key":"99837","unstructured":"Horn DB, Vu L, Porter BR, et al.: Responsible controlled substance and opioid prescribing. In StatPearls. Treasure Island, FL: StatPearls, 2025."},{"key":"99838","unstructured":"Ortiz NR, Preuss CV: Controlled Substance Act [updated February 9, 2024]. In StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2025. Available at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574544\/. Accessed October 17, 2025."},{"key":"99839","doi-asserted-by":"crossref","unstructured":"Schmidt TD, Haddox JD, Nielsen AE, et al.: Key data gaps regarding the public health issues associated with opioid analgesics. J Behav Health Serv Res. 2015; 42(4): 540-553. DOI: 10.1007\/s11414-014-9396-9.","DOI":"10.1007\/s11414-014-9396-9"},{"key":"99840","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021; 372: N71. DOI: 10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"99841","doi-asserted-by":"crossref","unstructured":"Dang A: Real-world evidence: A primer. Pharm Med. 2023;","DOI":"10.1007\/s40290-022-00456-6"},{"key":"99842","doi-asserted-by":"crossref","unstructured":"37(1): 25-36. DOI: 10.1007\/s40290-022-00456-6.","DOI":"10.1007\/s40290-022-00456-6"},{"key":"99843","doi-asserted-by":"crossref","unstructured":"Adams KK, Cohen SM, Guerra ME, et al.: Low-dose initiation of buprenorphine in hospitalized patients using buccal buprenorphine: A case series. J Addict Med. 2023; 17(4): 474-476. DOI: 10.1097\/ADM.0000000000001146.","DOI":"10.1097\/ADM.0000000000001146"},{"key":"99844","doi-asserted-by":"crossref","unstructured":"Zimmerman C, Clark S, Guerra ME, et al.: Low dose buprenorphine initiation: A guide for the inpatient clinician. Subst Abus. 2023; 44(3): 121-129. DOI: 10.1177\/08897077231196417.","DOI":"10.1177\/08897077231196417"},{"key":"99845","doi-asserted-by":"crossref","unstructured":"Aguilar B, Penm J, Liu S, et al.: Efficacy and safety of transdermal buprenorphine for acute postoperative pain: A systematic review and meta-analysis. J Pain. 2023; 24(11): 1905-1914. DOI: 10.1016\/j.jpain.2023.07.001.","DOI":"10.1016\/j.jpain.2023.07.001"},{"key":"99846","doi-asserted-by":"crossref","unstructured":"Brandt C, Atkinson TJ: A review of the safety of buprenorphine in special populations. Am J Med Sci. 2022; 364(6): 675-684. DOI: 10.1016\/j.amjms.2022.06.025.","DOI":"10.1016\/j.amjms.2022.06.025"},{"key":"99847","doi-asserted-by":"crossref","unstructured":"Vu PD, Bansal V, Chitneni A, et al.: Buprenorphine for chronic pain management: A narrative review. Curr Pain Headache Rep. 2023; 27(12): 811-820. DOI: 10.1007\/s11916-023-01185-4.","DOI":"10.1007\/s11916-023-01185-4"},{"key":"99848","doi-asserted-by":"crossref","unstructured":"Alexander D, Alexander K, Valentino J: Intranasal hydrocodone-acetaminophen abuse induced necrosis of the nasal cavity and pharynx. Laryngoscope. 2012; 122(11): 2378-2381. DOI: 10.1002\/lary.23542.","DOI":"10.1002\/lary.23542"},{"key":"99849","doi-asserted-by":"crossref","unstructured":"Ali MM, Tehrani AB, Mutter R, et al.: Factors associated with potentially problematic opioid prescriptions among individuals with private insurance and Medicaid. Addict Behav. 2019; 98: 106016. DOI: 10.1016\/j.addbeh.2019.06.005.","DOI":"10.1016\/j.addbeh.2019.06.005"},{"key":"99850","doi-asserted-by":"crossref","unstructured":"Anderson TL, Wagner J, Qi G, et al.: Prescription drug histories among drug overdose decedents in Delaware. Subst Use Misuse. 2020; 55(11): 1892-1899. DOI: 10.1080\/10826084.2020.1775650.","DOI":"10.1080\/10826084.2020.1775650"},{"key":"99851","doi-asserted-by":"crossref","unstructured":"Bonnecaze AK, Wilson MW, Dharod A, et al.: Acute kidney injury is common with intravenous abuse of extended-release oral oxymorphone and delayed renal recovery rates are associated with increased KDIGO staging. Nephrology. 2018; 23(10): 921-926. DOI: 10.1111\/nep.13153.","DOI":"10.1111\/nep.13153"},{"key":"99852","doi-asserted-by":"crossref","unstructured":"Cassidy TA, Thorley E, Black RA, et al.: Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder. J Opioid Manag. 2017; 13(6): 425-440. DOI: 10.5055\/jom.2017.0419.","DOI":"10.5055\/jom.2017.0419"},{"key":"99853","doi-asserted-by":"crossref","unstructured":"Cicero TJ, Ellis MS: Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin. JAMA Psychiatry. 2015; 72(5): 424-430. DOI: 10.1001\/jamapsychiatry.2014.3043.","DOI":"10.1001\/jamapsychiatry.2014.3043"},{"key":"99854","doi-asserted-by":"crossref","unstructured":"Cicero TJ, Mendoza M, Cattaneo M, et al.: Real-world misuse, abuse, and dependence of abuse-deterrent versus nonabuse-deterrent extended-release morphine in Medicaid non-cancer patients. Postgrad Med. 2019; 131(3): 225-229. DOI: 10.1080\/00325481.2019.1585688.","DOI":"10.1080\/00325481.2019.1585688"},{"key":"99855","doi-asserted-by":"crossref","unstructured":"Coplan PM, Kale H, Sandstrom L, et al.: Changes in oxycodone and heroin exposures in the national Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013; 22(12): 1274-1282. DOI: 10.1002\/pds.3522.","DOI":"10.1002\/pds.3522"},{"key":"99856","doi-asserted-by":"crossref","unstructured":"Gill JR, Lin PT, Nelson L: Reliability of postmortem fentanyl concentrations in determining the cause of death. J Med Toxicol. 2013; 9(1): 34-41. DOI: 10.1007\/s13181-012-0253-z.","DOI":"10.1007\/s13181-012-0253-z"},{"key":"99857","doi-asserted-by":"crossref","unstructured":"Krenzelok EP: Abuse of fentanyl derivatives: History repeating itself. Am J Health Syst Pharm. 2017; 74(8): 556-556. DOI: 10.2146\/ajhp170050.","DOI":"10.2146\/ajhp170050"},{"key":"99858","doi-asserted-by":"crossref","unstructured":"Kuhlman JJ, Harris C, Wright T: Buprenorphine prevalence in DUID cases in southwestern Virginia: Case studies and observations. J Anal Toxicol. 2022; 46(1): 89-98. DOI: 10.1093\/jat\/bkaa176.","DOI":"10.1093\/jat\/bkaa176"},{"key":"99859","doi-asserted-by":"crossref","unstructured":"Ng PC, Maddry JK, Sessions D, et al.: Using pill identification calls to poison centers as a marker of drug abuse at three Texas military bases. South Med J. 2017; 110(11): 722-724. DOI: 10.14423\/smj.0000000000000718.","DOI":"10.14423\/SMJ.0000000000000718"},{"key":"99860","doi-asserted-by":"crossref","unstructured":"Okic M, Cnossen L, Crifasi JA, et al.: Opioid overdose mortality in Kansas, 2001\u20132011: Toxicologic evaluation of intent. J Anal Toxicol. 2013; 37(9): 629-635. DOI: 10.1093\/jat\/bkt085.","DOI":"10.1093\/jat\/bkt085"},{"key":"99861","doi-asserted-by":"crossref","unstructured":"Paljarvi T, Strang J, Quinn PD, et al.: Abuse-deterrent extended-release oxycodone and risk of opioid-related harm. Addiction. 2021; 116(9): 2409-2415. DOI: 10.1111\/add.15392.","DOI":"10.1111\/add.15392"},{"key":"99862","doi-asserted-by":"crossref","unstructured":"Pfister GJ, Burkes RM, Guinn B, et al.: Opioid overdose leading to intensive care unit admission: Epidemiology and outcomes. J Crit Care. 2016; 35: 29-32. DOI: 10.1016\/j.jcrc.2016.04.022.","DOI":"10.1016\/j.jcrc.2016.04.022"},{"key":"99863","doi-asserted-by":"crossref","unstructured":"Vosburg SK, Beaumont J, Dailey-Govoni ST, et al.: Evaluation of abuse and route of administration of extended-release tapentadol among treatment-seeking individuals, as captured by the addiction severity index-multimedia version (ASI-MV). Pain Med. 2020; 21(9): 1891-1901. DOI: 10.1093\/pm\/pnz250.","DOI":"10.1093\/pm\/pnz250"},{"key":"99864","doi-asserted-by":"crossref","unstructured":"Cochran G, Bacci JL, Ylioja T, et al.: Prescription opioid use: Patient characteristics and misuse in community pharmacy. J Am Pharm Assoc. 2016; 56(3): 248-256.e6. DOI: 10.1016\/j.japh.2016.02.012.","DOI":"10.1016\/j.japh.2016.02.012"},{"key":"99865","doi-asserted-by":"crossref","unstructured":"Dart RC, Iwanicki JL, Dasgupta N, et al.: Do abuse deterrent opioid formulations work? J Opioid Manag. 2017; 13(6): 365-378. DOI: 10.5055\/jom.2017.0415.","DOI":"10.5055\/jom.2017.0415"},{"key":"99866","unstructured":"Servies T, Hu Z, Eick-Cost A, et al.: Substance Use Disorders in the US Armed Forces. Washington, DC: National Academies Press, 2000: 11-16."},{"key":"99867","doi-asserted-by":"crossref","unstructured":"Severtson SG, Bartelson BB, Davis JM, et al.: Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013; 14(10): 1122-1130. DOI: 10.1016\/j.jpain.2013.04.011.","DOI":"10.1016\/j.jpain.2013.04.011"},{"key":"99868","doi-asserted-by":"crossref","unstructured":"Soyka M: Buprenorphine and buprenorphine\/naloxone intoxication in children\u2014How strong is the risk? Curr Drug Abuse Rev. 2013; 6(1): 63-70. DOI: 10.2174\/18744737112059990010.","DOI":"10.2174\/18744737112059990010"},{"key":"99869","doi-asserted-by":"crossref","unstructured":"Wish ED, Artigiani E, Billing A, et al.: The emerging buprenorphine epidemic in the United States. J Addict Dis. 2012; 31(1) :3-7. DOI: 10.1080\/10550887.2011.642757.","DOI":"10.1080\/10550887.2011.642757"},{"key":"99870","doi-asserted-by":"crossref","unstructured":"Compton WM, Jones CM, Baldwin GT: Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016; 374(2): 154-163. DOI: 10.1056\/NEJMra1508490.","DOI":"10.1056\/NEJMra1508490"},{"key":"99871","doi-asserted-by":"crossref","unstructured":"Heltsley R, DePriest A, Black DL, et al.: Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J Anal Toxicol. 2011; 35(8): 529-540. DOI: 10.1093\/anatox\/35.8.529.","DOI":"10.1093\/anatox\/35.8.529"},{"key":"99872","doi-asserted-by":"crossref","unstructured":"Qeadan F, Madden EF, Mensah NA, et al.: Epidemiological trends in opioid-only and opioid\/polysubstance-related death rates among American Indian\/Alaska Native populations from 1999 to 2019: A retrospective longitudinal ecological study. BMJ Open. 2022; 12(5): e053686. DOI: 10.1136\/bmjopen-2021-053686.","DOI":"10.1136\/bmjopen-2021-053686"},{"key":"99873","doi-asserted-by":"crossref","unstructured":"Ray B, Quinet K, Dickinson T, et al.: Examining fatal opioid overdoses in Marion County, Indiana. J Urban Health. 2017; 94(2): 301-310. DOI: 10.1007\/s11524-016-0113-2.","DOI":"10.1007\/s11524-016-0113-2"},{"key":"99874","doi-asserted-by":"crossref","unstructured":"Acharya M, Hayes CJ, Li C, et al.: Development of a potential opioid misuse measure from administrative dispensing data and contrasting opioid misuse among individuals on long-term tramadol, long-term short-acting hydrocodone or long-term short-acting oxycodone therapy in Arkansas. Curr Med Res Opin. 2022; 38(11): 1947-1957. DOI: 10.1080\/03007995.2022.2112874.","DOI":"10.1080\/03007995.2022.2112874"},{"key":"99875","doi-asserted-by":"crossref","unstructured":"Alexander C, Breuel K, Olsen M: High prevalence of buprenorphine in prenatal drug screens in an Appalachian city. South Med J. 2020; 113(3): 111-115. DOI: 10.14423\/smj.0000000000001072.","DOI":"10.14423\/SMJ.0000000000001072"},{"key":"99876","doi-asserted-by":"crossref","unstructured":"Allen JD, Casavant MJ, Spiller HA, et al.: Prescription opioid exposures among children and adolescents in the United States: 2000-2015. Pediatrics. 2017; 139(4). DOI: 10.1542\/peds.2016-3382.","DOI":"10.1542\/peds.2016-3382"},{"key":"99877","doi-asserted-by":"crossref","unstructured":"Caupp S, Steffan J, Shi J, et al.: Opioid drug poisonings in Ohio adolescents and young adults, 2002-2014. Clin Toxicol (Phila). 2018; 56(8): 765-772. DOI: 10.1080\/15563650.2018.1424889.","DOI":"10.1080\/15563650.2018.1424889"},{"key":"99878","doi-asserted-by":"crossref","unstructured":"Chung CP, Callahan ST, Cooper WO, et al.: Individual short-acting opioids and the risk of opioid-related adverse events in adolescents. Pharmacoepidemiol Drug. 2019; 28(11): 1448-1456. DOI: 10.1002\/pds.4872.","DOI":"10.1002\/pds.4872"},{"key":"99879","doi-asserted-by":"crossref","unstructured":"Coplan PM, Sessler NE, Harikrishnan V, et al.: Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. Postgrad Med. 2017; 129(1): 55-61. DOI: 10.1080\/00325481.2017.1269596.","DOI":"10.1080\/00325481.2017.1269596"},{"key":"99880","doi-asserted-by":"crossref","unstructured":"Dart RC, Cicero TJ, Surratt HL, et al.: Assessment of the abuse of tapentadol immediate release: The first 24 months. J Opioid Manag. 2012; 8(6): 395-402. DOI: 10.5055\/jom.2012.0139.","DOI":"10.5055\/jom.2012.0139"},{"key":"99881","doi-asserted-by":"crossref","unstructured":"Green JL, Dailey-Govoni T, Butler SF: Real-world data on nonmedical use of tramadol from patients evaluated for substance abuse treatment in the NAVIPPRO addiction severity Index-Multimedia version (ASI-MV(\u00ae)) network. Drug Saf. 2021; 44(2): 235-244. DOI: 10.1007\/s40264-020-01012-4.","DOI":"10.1007\/s40264-020-01012-4"},{"key":"99882","doi-asserted-by":"crossref","unstructured":"Karami S, Ajao A, Wong J, et al.: The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deaths. Pharmacoepidemiol Drug. 2023; 32(7): 735-751. DOI: 10.1002\/pds.5603.","DOI":"10.1002\/pds.5603"},{"key":"99883","doi-asserted-by":"crossref","unstructured":"Land ME, Wetzel M, Geller RJ, et al.: Adult opioid poisonings by drug, intent, and resource use from the United States National Poison Data System from 2005-2018. Clin Toxicol (Phila). 2021; 59(2): 142-151. DOI: 10.1080\/15563650.2020.1781150.","DOI":"10.1080\/15563650.2020.1781150"},{"key":"99884","doi-asserted-by":"crossref","unstructured":"Lovegrove MC, Dowell D, Geller AI, et al.: US emergency department visits for acute harms from prescription opioid use, 2016-2017. Am J Public Health. 2019; 109(5): 784-791. DOI: 10.2105\/ajph.2019.305007.","DOI":"10.2105\/AJPH.2019.305007"},{"key":"99885","doi-asserted-by":"crossref","unstructured":"Piper BJ, Desrosiers CE, Fisher HC, et al.: A new tool to tackle the opioid epidemic: Description, utility, and results from the Maine diversion alert program. Pharmacotherapy. 2017; 37(7): 791-798. DOI: 10.1002\/phar.1952.","DOI":"10.1002\/phar.1952"},{"key":"99886","doi-asserted-by":"crossref","unstructured":"Rzetelny A, Meske D, Patel P, et al.: Tapentadol is the least common opioid found in admission urine drug-test results at an intensive outpatient opioid-use disorder treatment program in Ohio: A brief report. J Opioid Manag. 2021; 17(1): 13-17. DOI: 10.5055\/jom.2021.0610.","DOI":"10.5055\/jom.2021.0610"},{"key":"99887","doi-asserted-by":"crossref","unstructured":"Simpson KJ, Moran MT, Foster ML, et al.: Descriptive, observational study of pharmaceutical and non-pharmaceutical arrests, use, and overdoses in Maine. BMJ Open. 2019; 9(4): e027117. DOI: 10.1136\/bmjopen-2018-027117.","DOI":"10.1136\/bmjopen-2018-027117"},{"key":"99888","doi-asserted-by":"crossref","unstructured":"Simpson KJ, Moran MT, McCall KL, et al.: Increasing heroin, cocaine, and buprenorphine arrests reported to the Maine diversion alert program. Forensic Sci Int. 2019; 303: 109924. DOI: 10.1016\/j.forsciint.2019.109924.","DOI":"10.1016\/j.forsciint.2019.109924"},{"key":"99889","doi-asserted-by":"crossref","unstructured":"Wiegand TJ, Le Lait MC, Bartelson BB, et al.: Analysis of the abuse and diversion of the buprenorphine transdermal delivery system. J Pain. 2016; 17(6): 745-752. DOI: 10.1016\/j.jpain.2016.02.015.","DOI":"10.1016\/j.jpain.2016.02.015"},{"key":"99890","doi-asserted-by":"crossref","unstructured":"Hale M, Garofoli M, Raffa RB: Benefit-risk analysis of buprenorphine for pain management. J Pain Res. 2021; 14: 1359-1369. DOI: 10.2147\/JPR.S305146.","DOI":"10.2147\/JPR.S305146"},{"key":"99891","doi-asserted-by":"crossref","unstructured":"Green JL, Bucher Bartelson B, Le Lait MC, et al.: Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend. 2017; 175: 140-145. DOI: 10.1016\/j.drugalcdep.2017.01.039.","DOI":"10.1016\/j.drugalcdep.2017.01.039"},{"key":"99892","doi-asserted-by":"crossref","unstructured":"Birt J, Johnston J, Nelson D: Exploration of claims-based utilization measures for detecting potential nonmedical use of prescription drugs. J Manag Care Spec Pharm. 2014; 20(6): 639-646. DOI: 10.18553\/jmcp.2014.20.6.639.","DOI":"10.18553\/jmcp.2014.20.6.639"}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3980\/4264","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3980\/4264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:02:32Z","timestamp":1771974152000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/3980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.0967","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"value":"1551-7489","type":"electronic"},{"value":"1551-7489","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}